Scope
Treatment options for RA have advanced over the past two decades, resulting in a crowded,
competitive market landscape.
- What is the pathophysiology of RA?
- Which products and therapeutic strategies dominate the clinical and commercial landscapes?
- What are the most significant unmet needs within the RA market?
Considerable diversification from current market trends is evident within the RA pipeline.
- Which molecular targets are most prominent within the pipeline?
- What proportion of pipeline products are first in class?
- Which first-in-class targets are most promising?
Deal values for licensing and co-development deals vary considerably.
- How many strategic consolidations have been completed in the past decade?
- Which types of assets attract the largest deal values?
- Which first-in-class pipeline products have no prior involvement in licensing or co-development
deals?
Related reports by Radiant Insights:
http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
Reasons to buy
This report will allow you to -
- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis,
etiology, epidemiology, symptoms, co-morbidities and complications, diagnosis, and treatment
options.
- Visualize the composition of the RA landscape, including key unmet needs, in order to gain a
competitive understanding of gaps in the current market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule
type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, all first-in-
class targets in the RA pipeline have been assessed and ranked according to clinical potential.
Promising early-stage targets have been further reviewed in greater detail.
Follow Us: